NICE publish final guidance for idelalisib to treat CLL, moving England and Wales NHS access closer

NICE published Final Guidance today on Idelalisib for treating chronic lymphocytic leukaemia

NICE technology appraisal guidance [TA359]


This publishing of final guidance moves the treatment of idelalisib plus rituximab one step closer to NHS availability for England and Wales patients with NHS access expected within 3 months.


 The new treatment offers and option for hard to treat patients living with chronic lymphocytic leukaemia who are untreated and have a 17p deletion or TP53 mutation or for chronic lymphocytic leukaemia  patients that have been treated but have relapsed within 24 months.


About the Final Apraisal Decisicon (FAD) NICE approves idelalisib (Zydelig®) for the treatment of chronic lymphocytic leukaemia in England and Wales